Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways (CMPS) reported new 52‑week topline open‑label Part C data from its Phase 3 COMP005 trial of COMP360 psilocybin in treatment‑resistant depression.
Participants originally randomized to the 25 mg arm who received an additional 25 mg dose in Part C achieved an average 13‑point MADRS reduction from baseline at Week 52, extending durability of effect out to one year. Prior placebo‑arm participants who received their first 25 mg dose in Part C showed a meaningful 10‑point average MADRS reduction by the end of Part C, supporting rapid and durable effects from a single dose. Across all Part C participants who received 25 mg, 40%–45% met response criteria and approximately 30% achieved remission at all timepoints through six weeks post‑dose. The safety profile remained generally well tolerated with no new safety findings. A rolling NDA submission is underway, with final submission expected in Q4 and a potential U.S. launch in the first half of 2027, subject to FDA approval.
Compass Pathways (CMPS) will participate in Psych Congress 2026 in New Orleans from September 14-19, debuting its new U.S. HCP education campaign, Change the Tune in TRD, focused on treatment-resistant depression (TRD).
The campaign will launch in a three‑panel Innovation Theater session on September 15 from 12:15–1:30pm in Room 220-222, featuring Saundra Jain, Bryan B. Shapiro, and Sandhya Prashad. Compass will also present seven poster sessions, including new health economics and outcomes research (HEOR) data on TRD and encore analyses from its COMP360 psilocybin Phase 3 clinical program. Company activities include a disease state booth (#901) and a medical booth (#937).
Compass Pathways (CMPS) granted new employee inducement equity awards under its 2026 Inducement Plan on 1 September 2026 to thirty-one newly hired non-executive employees.
The grants include options to purchase an aggregate of 280,600 shares and restricted share units or UK nominal cost options covering 133,500 shares. The options have an exercise price of $13.24, equal to the closing price of the company’s ADSs on the grant date. Options vest over four years, with 25% after one year and the remaining 75% in equal monthly installments over three years, subject to continued employment. RSUs and nominal cost options vest in four equal annual installments. The awards were approved under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.
Compass Pathways (CMPS) has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare, recognizing organizations advancing medicine and reshaping biopharma and healthcare.
The company is developing COMP360 synthetic psilocybin for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), supported by data from three late-stage trials in more than 1,000 TRD participants. A rolling New Drug Application submission and review for TRD is underway with the U.S. FDA, and commercial launch preparations are progressing toward an anticipated first-half 2027 launch, subject to regulatory approval. COMP360 holds Breakthrough Therapy designation from the FDA and ILAP designation in the UK for TRD.
Compass Pathways (Nasdaq: CMPS) will participate in the 2026 Cantor Global Healthcare Conference on September 9, 2026, joining a fireside chat at 3:20pm ET and a psychedelics access panel at 4:30pm ET. A live audio webcast and 30-day replay will be available via the company’s investor events webpage.
Compass Pathways (Nasdaq: CMPS) announced that management will attend Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, featuring a fireside chat at 8:00am ET. Management will also participate in the Stifel Biotech Summit in Newport, Rhode Island, on August 10, 2026.
According to Compass Pathways, a live audio webcast and 30-day replay for each event will be available on the Investors “Events” page. The company is developing its investigational COMP360 psilocybin treatment for treatment-resistant depression and post-traumatic stress disorder, with FDA Breakthrough Therapy and UK ILAP designations for TRD.
Compass Pathways (Nasdaq: CMPS) announced it is working with the U.S. Department of Veterans Affairs on PIVOT, a multi-site, double-blind, randomized controlled trial of its investigational COMP360 psilocybin in veterans with treatment-resistant depression (TRD), including those with concurrent post-traumatic stress disorder (PTSD).
The VA-led study will compare two COMP360 dose levels, with an option for a second open-label administration after four weeks. The primary endpoint is depression severity measured by the MADRS scale, with secondary outcomes including PTSD symptoms, tolerability, and patient-reported depression. Compass will donate COMP360 and provide training materials, guidance and consultation for investigators across five VA sites.
Compass Pathways (Nasdaq: CMPS) granted new employee equity awards under its 2026 Inducement Plan to fourteen newly hired non-executive employees. On August 3, 2026, the company issued options to purchase an aggregate of 139,355 shares and restricted share units or UK nominal cost options covering 66,300 shares.
The options have an exercise price of $11.25, equal to the Nasdaq closing price on the grant date, and vest over four years (25% after one year, then monthly over three years), subject to continued employment. RSUs and nominal cost options vest in four equal annual installments. According to Compass Pathways, the awards were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements to employment, and complement its focus on developing COMP360 psilocybin for treatment-resistant depression and PTSD.
Compass Pathways (Nasdaq: CMPS) reported second quarter and first half 2026 results and detailed progress on COMP360 psilocybin therapy for treatment-resistant depression (TRD) and PTSD. Two positive Phase 3 TRD trials showed rapid onset and durable benefit through at least 6 months, with clinically meaningful MADRS reductions observed from the day after dosing and maintained on average to Week 26. COMP360 was generally well tolerated, with mostly transient, dosing-day adverse events and low serious adverse event rates.
According to Compass, rolling NDA submission and initial FDA review for COMP360 are underway, with final submission on track for Q4 2026, supported by a National Priority Voucher that may shorten review. Commercial launch is expected in first half 2027, subject to FDA approval and DEA rescheduling. A late-stage PTSD trial is ongoing. Q2 2026 research and development expense was $29.2 million and general and administrative expense was $23.2 million. Net loss was $253.8 million, or $1.88 per share, largely driven by a $205.6 million non-cash fair value loss on warrants. Cash and cash equivalents were $433.3 million and debt was $50.7 million at June 30, 2026, and Compass expects its cash to fund operations into 2028.
Compass Pathways (Nasdaq: CMPS) will release its second quarter and first half 2026 financial results for the period ended June 30, 2026, on August 5, 2026. Management will host a conference call at 8:00 am ET (1:00 pm UK), with a live webcast available on the company’s website and archived for 30 days.
Compass Pathways is developing COMP360 psilocybin, a proprietary investigational treatment for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 has FDA Breakthrough Therapy and UK ILAP designations for TRD, and is being studied in large clinical programs in TRD and a late-stage trial in PTSD.